| Profiles RNS

Profile

MD, New York University School of Medicine
AB, Harvard College

Websites

	LinkedIn
	Hartford Hospital

ORCID : 0000-0002-9141-553X

BU Research
BMC Research

A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
02/01/2010 - 01/31/2017 (PI)
Bayer AG

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
03/10/2010 - 03/09/2013 (PI)
GlaxoSmithKline LLC

Expanded Access Program with Nivolumab for subjects with Histologically confirmed Stage III…
12/02/2014 - 12/02/2019 (PI)
Bristol-Myers

Title

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019 09 03; 7(1):235. PMID: 31481112

White PS, Pudusseri A, Lee SL, Eton O. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports. Thyroid. 2017 Sep; 27(9):1201-1205.View Related Profiles.

Eton, Omar
Lee, Stephanie

PMID: 28805135; PMCID: PMC6874808; DOI: 10.1089/thy.2017.0106;

Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother. 2012 Oct; 12(10):1207-15.View Related Profiles.

Kasper, Ekkehard
Eton, Omar

PMID: 23082737; DOI: 10.1586/ern.12.111;

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther. 2010 Oct; 9(10):2844-52. PMID: 20724522; DOI: 10.1158/1535-7163.MCT-10-0299;

Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr; 67(4):945-54. PMID: 20607239; PMCID: PMC3026871; DOI: 10.1007/s00280-010-1377-y;

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med. 2010; 8:9. PMID: 20109236; PMCID: PMC2835652; DOI: 10.1186/1479-5876-8-9;

Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2009 Aug; 4(8):1002-9. PMID: 19633475; DOI: 10.1097/JTO.0b013e3181aba89f;

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9. PMID: 19430405; DOI: 10.1097/CMR.0b013e328314b84a;

Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 2; 99(5):734-40. PMID: 18728664; PMCID: PMC2528157; DOI: 10.1038/sj.bjc.6604482;

Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307; DOI: 10.1097/CMR.0b013e3283046146;

Showing 10 of 51 results. Show More

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006 May 1; 106(9):2005-11. PMID: 16565971

Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 2006 Apr; 33(4):280-5. PMID: 16630177

Eton O. Chemotherapy, cytokines, and biochemotherapy for melanoma. Cancer Chemother Biol Response Modif. 2005; 22:739-48. PMID: 16110637

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer. 2004 Aug 1; 101(3):596-603. PMID: 15274073

Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 1; 100(7):1478-83. PMID: 15042682

Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004 Feb; 14(1):63-6. PMID: 15091196

McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5. PMID: 15009722

Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol. 2003 Oct; 30(9):539-47. PMID: 14507401

Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003 Jun; 13(3):303-6. PMID: 12777987

Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer. 2002 Jul 1; 95(1):127-34. PMID: 12115326

Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15; 20(8):2045-52. PMID: 11956264

Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs. 2002 Feb; 13(2):169-72. PMID: 11901310

Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 2001 Apr; 11(2):183-8. PMID: 11333129

Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000 Oct; 6(10):3895-903. PMID: 11051235

Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer. 2000 Apr 1; 88(7):1703-9. PMID: 10738230

Eton O, East M, Legha SS, Bedikian A, Buzaid AC, Papadopoulos N, Hodges C, Gianan M, Carrasco CH, Benjamin RS. Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases. Melanoma Res. 1999 Oct; 9(5):483-9. PMID: 10596915

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S, Viallet J. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs. 1999 Sep; 10(8):735-9. PMID: 10573206

Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep. 1999 Sep-Oct; 6(5):1097-9. PMID: 10425308

Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998 Dec; 8(6):549-56. PMID: 9918417

Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res. 1998 Oct; 4(10):2363-70. PMID: 9796966

Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998 May; 16(5):1752-9. PMID: 9586888

Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998 Apr; 8(2):149-55. PMID: 9610868

Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res. 1998 Apr; 8(2):145-8. PMID: 9610867

Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998 Mar; 16(3):1103-11. PMID: 9508197

Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res. 1998 Mar; 4(3):619-27. PMID: 9533529

Yeung SC, Eton O, Burton DW, Deftos LJ, Vassilopoulou-Sellin R, Gagel RF. Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma. Horm Res. 1998; 49(6):288-91. PMID: 9623520

Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S9-15. PMID: 9457387

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol. 1997 Apr; 8(4):363-7. PMID: 9209666

Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997 Mar; 15(3):1039-51. PMID: 9060544

Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996 Oct; 7(8):827-35. PMID: 8922197

Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17. PMID: 8811495

Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Cancer. 1996 Mar 1; 77(5):893-9. PMID: 8608480

Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996 Jan 1; 77(1):89-96. PMID: 8630945

Bedikian AY, Weiss GR, Legha SS, Burris HA, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995 Dec; 13(12):2895-9. PMID: 8523052

Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñez NG, Smith JL, Eton O, Ross M, Grimm EA. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res. 1995 Apr; 15(4):331-40. PMID: 7627808

Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res. 1994 Oct; 4(5):327-30. PMID: 7858418

Umezu Y, Augustus LB, Seito D, Hayakawa K, Ross MI, Eton O, Swanson DA, Itoh K. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation. Cancer Immunol Immunother. 1993 Nov; 37(6):392-9. PMID: 8242664

Eton O, Legha SS, Balch CM. Cutaneous melanoma. N Engl J Med. 1992 Jan 30; 326(5):345-6; author reply 346-7. PMID: 1728744

Eton O, Bajorin DF, Casper ES, Houghton AN. Phase II trial of N-methylformamide in patients with metastatic melanoma. Invest New Drugs. 1991 Feb; 9(1):97-100. PMID: 2026491

Eton O, Bajorin DF, Chapman PB, Cody BV, Houghton AN. Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. Invest New Drugs. 1991 Feb; 9(1):101-3. PMID: 2026478

Eton O, Scheinberg DA, Houghton AN. Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia. 1989 Oct; 3(10):729-35. PMID: 2506399

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Available to Mentor as: (Review Mentor Role Definitions):

Advisor
Career Mentor
Co-Mentor or Peer Mentor
Project Mentor
Research / Scholarly Mentor

Contact for Mentoring: